172 related articles for article (PubMed ID: 38164785)
1. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo D; Tinajero J; Li S; Palmer J; Pourhassan H; Aribi A; Nakamura R; Stein A; Marcucci G; Salhotra A; Sandhu K; Pullarkat V; Ball B; Koller P
Leuk Lymphoma; 2024 Mar; 65(3):372-377. PubMed ID: 38164785
[TBL] [Abstract][Full Text] [Related]
2. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
[TBL] [Abstract][Full Text] [Related]
4. Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Zucenka A; Griskevicius L
Br J Haematol; 2024 Apr; 204(4):1227-1231. PubMed ID: 38291741
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
7. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Kugler E; Cohen I; Amitai I; Ram R; Frisch A; Nachmias B; Canaani J; Moshe Y; Krayem B; Aumann S; Henig I; Vainstein V; Shargian L; Ganzel C; Yeshurun M; Levi I; Raanani P; Akria L; Ofran Y; Shimony S; Wolach O
Br J Haematol; 2024 May; ():. PubMed ID: 38782575
[TBL] [Abstract][Full Text] [Related]
8. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Recher C; Yoon SS; Maeda Y; Hosono N; Onozawa M; Kato T; Kim HJ; Hasabou N; Nuthethi R; Tiu R; Levis MJ
Transplant Cell Ther; 2023 Apr; 29(4):265.e1-265.e10. PubMed ID: 36526260
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
10. Gilteritinib or Chemotherapy for Relapsed or Refractory
Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
[TBL] [Abstract][Full Text] [Related]
11. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
12. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
13. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
15. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
McMahon CM; Perl AE
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
[No Abstract] [Full Text] [Related]
16. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Sandhu KS; Dadwal S; Yang D; Mei M; Palmer J; Salhotra A; Al Malki M; Aribi A; Ali H; Khaled S; Forman SJ; Snyder D; Nakamura R; Stein AS; Marcucci G; Aldoss I; Pullarkat V
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e322-e327. PubMed ID: 32866594
[TBL] [Abstract][Full Text] [Related]
18. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
[TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.
Tzogani K; Røshol H; Olsen HH; Aas IB; Dalhus ML; Håkonsen GD; Nilssen LS; Lindberg V; Økvist M; Bolstad B; Rogovska I; Karpova N; Enzmann H; Gisselbrecht C; Pignatti F
Oncologist; 2020 Jul; 25(7):e1070-e1076. PubMed ID: 32154636
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
